Kevin Punie
- Oncology top 1%
- HER2/EGFR in Cancer Research 33
- Cancer Treatment and Pharmacology 27
- Cancer Immunotherapy and Biomarkers 17
- COVID-19 and healthcare impacts 7
- Cancer Research top 2%
- Breast Cancer Treatment Studies 29
- Cancer Genomics and Diagnostics 13
- Immunology top 5%
-
- Advanced Breast Cancer Therapies 32
-
- Radiopharmaceutical Chemistry and Applications 8
- Co-authors
- Hans WildiersPatrick NevenAnn SmeetsGiuseppe FlorisCarlos H. BarriosNadia HarbeckVidya MaiyaAndreas Koehler
- Cited by
- OncologyCancer ResearchImmunology
- Partner nations
- BelgiumUnited StatesFrance
In The Last Decade
Kevin Punie
102 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Oncology 1.9k
- Cancer Research 659
- Immunology 530
- Pulmonary and Respiratory Medicine 639
- Radiology, Nuclear Medicine and Imaging 264
Countries citing papers authored by Kevin Punie
This map shows the geographic impact of Kevin Punie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Punie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Punie more than expected).
Fields of papers citing papers by Kevin Punie
This network shows the impact of papers produced by Kevin Punie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Punie. The network helps show where Kevin Punie may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kevin Punie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 35 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 0 | |
| 6 | 2023 | 4 | |
| 7 | 2022 | 2 | |
| 8 | 2022 | 2 | |
| 9 | 2022 | 9 | |
| 10 | 2022 | 37 | |
| 11 | 2021 | 3 | |
| 12 | 2021 | 44 | |
| 13 | 2021 | 6 | |
| 14 | A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancerbreakdown → | 2021 | 442 |
| 15 | 2021 | 7 | |
| 16 | 2020 | 9 | |
| 17 | 2020 | 8 | |
| 18 | 2020 | 6 | |
| 19 | 2019 | 1 | |
| 20 | 2017 | 40 |
About Kevin Punie
Kevin Punie is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 113 papers that have together received 2.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (33 papers), Advanced Breast Cancer Therapies (32 papers), Breast Cancer Treatment Studies (29 papers), Cancer Treatment and Pharmacology (27 papers), Cancer Immunotherapy and Biomarkers (17 papers), Cancer Genomics and Diagnostics (13 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and COVID-19 and healthcare impacts (7 papers). The work is most often cited by research in Oncology (1.9k citations), Cancer Research (659 citations) and Immunology (530 citations). Kevin Punie has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Hans Wildiers, Patrick Neven, Ann Smeets, Giuseppe Floris, Carlos H. Barrios, Nadia Harbeck, Vidya Maiya, Andreas Koehler, Shilpen Patel and Kyung Hae Jung. Their work appears in journals such as New England Journal of Medicine, The Lancet and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.